PeptideStack
5.2kquestions
20kanswers
220users

Does testing every lot make sense, or every third lot?

Asked 5 Jul 2025Modified 10 months agoViewed 24k times
24

The lot number on the vial matches the certificate, which at least rules out the easy problem.

I would like to set this up properly once, rather than adjust it repeatedly.

My budget is real but not tight, and my tolerance for uncertainty is low.

What should I decide now, and what should I defer?

batch-testing
batch-testing

Testing at the batch or lot level: sampling plans, how many vials from a lot need testing to say anything about the lot, and the difference…

865 questions
cost-analysis
cost-analysis

Cost arithmetic done honestly: cost per milligram after dead-space loss, list versus net price, comparing a multi-dose vial to a fixed-dose pen,…

261 questions
harm-reduction
harm-reduction

Reducing avoidable risk where a decision has already been made: independent verification before use, sterility practice, dose arithmetic checked…

445 questions
shareeditfollowflag
RT
askedrune_thoresen14k185 Jul 2025
3This matches what I was told by a laboratory, for whatever that is worth. – ines_brandt 2 months ago
2Minor: the trial name is hyphenated in the original publication. – esther_vandeVelde 5 hours ago
add a comment

5 Answers

Sorted by votes
58

Two vials tested from a lot of ten is very different from two vials tested from a lot of ten thousand, and most certificates do not state the lot size.

A statement that "lot 20260412 complies with specifications" is meaningless without stating which vials from the lot were tested and how many there were.

What each test answers

TestAnswersDoes NOT answer
RP-HPLC, area %What fraction of detected material is the targetHow much target is present
Quantified contentMilligrams of peptide per vialWhat the impurities are
ESI-MS identityWhether the molecular weight matchesPurity, or isomeric substitution
Peptide mappingSequence, localised to a fragmentQuantity
Karl FischerWater content of the solidSolvent content
LAL endotoxinPyrogen load in EU/mgSterility
Sterility testGrowth in defined media over 14 daysEndotoxin, or bioburden count

If the entire lot failed qualification, a retest on a different vial is sometimes done, but reporting a retest result under the same lot number is misleading.

One qualification: testing more vials gives better confidence, but at some point the cost outweighs the benefit.

If testing multiple vials, state how many you tested and why you chose those vials.

edited 4 Sept 2025 by area_percent — updated for the 2026 guidance change

shareimprove this answerflag
AP
answeredarea_percent13k1811 Aug 2025
Sponsored

PeptideMeter - Independent Peptide Analytics

Aggregated, published test results and vendor ratings built from submitted batches. Methodology stated, dataset browsable, no listing fees.

Browse results
38

The underlying point is that thermal history during shipping is different for every vial, so a lot that experienced thermal abuse may have internal variation even if it was originally homogeneous.

If you have reason to suspect inhomogeneity — different appearance in different vials, or a long or warm shipment — testing more vials is the diagnostic move.

Stratified sampling — testing one vial from the top, one from the middle, and one from the bottom of a shipment — is cheap insurance against segregation.

Lyophilised peptide homogeneity studies show that vial-to-vial variation is usually small but occasionally large, depending on the distribution in the freeze-dryer.

The limitation is that you cannot know for certain without testing every vial, and you almost never can afford to do that.

The practical summary: a lot number without a sampling statement is a lot number without meaning.

shareimprove this answerflag
WO
answeredw_okoye40k13822 Aug 2025
6The timing signature is the useful part. Everything else is confounded. – s_bhattacharya 3 months ago
add a comment
30

More usefully, if a lot has visibly segregated — some vials showing different appearance — then sampling the top and bottom of the shipment is worth doing.

If the lot was manufactured in multiple batches, testing vials from each batch separately establishes whether batch-to-batch variation is acceptable.

The statistical foundation here is well-established, which is why sampling plans from decades ago are still valid.

Sampling plans for pharmaceutical manufacturing are defined in ISO 2859 and ANSI Z1.4, and they are based on statistical sampling theory.

The caveat is that sampling is a trade-off between cost and confidence, and neither test nor assumption is cost-free.

Assume segregation is possible, and design your sampling to catch it if it exists.

shareimprove this answerflag
DL
answeredDr_Otto_Lindqvist38k383 Sept 2025
7I would gently push back on the second point — the evidence there is thinner than stated. – Dr_Yusuf_Adeyemi 40 days ago
6Adding for future readers: the certificate should carry the lot number, not just a batch code. – bufferline42 10 months ago
add a comment
24

The honest statement is that unless you have tested multiple vials or have segregation data, you are making an assumption about lot homogeneity that may not hold.

Acceptance Sampling by Attributes defines the number of samples you need from a lot to claim a specified quality level at a specified risk — it is in ANSI standard Z1.4.

Published data on lot homogeneity from manufacturers who sample multiple vials consistently find variation below the published specifications, suggesting the sampling plans work.

Worth noting that thermal excursions during shipping affect different vials differently, so the lot may not be homogeneous even if it left the factory that way.

If testing multiple vials, state how many you tested and why you chose those vials.

shareimprove this answerflag
P9
answeredplate_count_9k95k15814 Sept 2025
Good answer, but the confidence interval in the cited trial is wider than implied. – bufferline42 7 months ago
add a comment
18

The practical consequence is that spot-testing one vial from a new supplier is better than assuming they are all the same.

For a quantitative result like content, the acceptable range determines how many vials you need to test to establish the lot complies.

Lyophilised peptide homogeneity studies show that vial-to-vial variation is usually small but occasionally large, depending on the distribution in the freeze-dryer.

I would treat a "complies with" statement without sampling details as a claim rather than as evidence.

The practical summary: a lot number without a sampling statement is a lot number without meaning.

shareimprove this answerflag
IB
answeredines_brandt93k24825 Sept 2025

Your answer

Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.

Not medical advice. Research-use-only compounds are not approved for human use.